Skip to content

Bilateral Percutaneous Nephrolithomy

A Prospective Trial of Feasibility and Efficacy of Simultaneous Bilateral Percutaneous Nephrolithotomy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03924362
Enrollment
92
Registered
2019-04-23
Start date
2019-09-30
Completion date
2023-12-31
Last updated
2022-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrolithiasis of Both Kidneys

Brief summary

The purpose of this study is to determine the effective regimen for definitive surgical therapy of bilateral kidney stones. It is unknown whether patients who undergo simultaneous bilateral percutaneous nephrolithotomy (PCNL) experience improved post-operative outcomes compared to patients who have staged unilateral procedures.

Detailed description

Purpose: The aim of this research is to determine an effective regimen for definitive surgical therapy of bilateral kidney stones. It is unknown whether patients who undergo simultaneous bilateral percutaneous nephrolithotomy (PCNL) experience improved post-operative outcomes compared to patients who have staged unilateral procedures. Hypothesis and Justification The gold standard for surgical management of large kidney stones is percutaneous nephrolithotomy (PCNL). A large renal stone burden has been defined as \>20mm. In addition, PCNL has improved stone-free rates for lower pole calculi \>10mm compared to alternative treatments. Guidelines encourage removal of staghorn calculi for surgical candidates (Assimos et al., 2016). Patients with bilateral large stone burdens have been managed with one of two general options: (i) a single procedure in which both kidneys are operated upon or (ii) two separate procedures in which only one kidney is addressed per procedure. However, there are no prospectively performed peer-reviewed studies directly comparing the two practices. The investigators seek to determine whether there is a significant difference in patient outcomes based on the surgical regimen chosen. The investigators hypothesize that in comparison to unilateral PCNL (U-PCNL), simultaneous bilateral PCNL (SB-PCNL) under one anesthetic results in comparable 1. stone free rates 2. re-intervention rates for residual stones and 3. perioperative complication rates Objectives The objectives are: 1. To provide clinical data on outcomes following simultaneous bilateral and staged percutaneous nephrolithotomy for renal and ureteral calculi 2. To determine patient preference with respect to simultaneous versus staged PCNL Research Design This study will be a prospective, non-randomized, multi-centre, non-blinded trial. Participants will be accrued through the Vancouver General Hospital Stone Center who have been referred for bilateral stones or have been seen in consultation for bilateral stones at the Department of Urologic Sciences and are scheduled for a percutaneous nephrolithotomy (PCNL). Consent forms and Letters of Introduction outlining the study will be given to patients by a research coordinator once the decision is made to book surgery. Patients will have at least 24 hours to decide to participate. Patients will receive surgical management for their stones in the form of PCNL. A computed tomography (CT) scan of the kidneys will be performed post-operatively by week 6 to determine if any residual stone fragments are present. Patients will be seen in follow up at 3 months in clinic after undergoing a follow up CT KUB, renal ultrasound, or KUB as necessary to evaluate stone clearance.

Interventions

PROCEDUREPCNL

Percutaneous Nephrolithotomy is a means of treating large kidney stone burdens.

Sponsors

University of British Columbia
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Patients will be managed either with simultaneous bilateral procedures or staged unilateral procedures based on surgeon's routine practice pattern. Additional surgical interventional will be dependent on initial patient stone-free outcomes.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

All subjects with a clinical diagnosis of struvite calculi will potentially be included. Specific inclusion criteria include the following: 1. Age \>18 years 2. Any patient with bilateral stone burden eligible and appropriate for PCNL procedure 3. Medically fit for definitive surgical management of stone.

Exclusion criteria

Patients with any of the following characteristics will not be eligible for the present study: 1. Those with medical comorbidities preventing them from safely undergoing definitive surgical therapy. 2. Patients who are unable to provide informed consent. 3. Patients who are planned for alternative procedures (ureteroscopy, extracorporeal shock wave lithotripsy) 4. Anyone who is unable to give their informed consent 5. Anyone under the age of 19 6. Anyone who, in the opinion of the PI, is unfit or unsuitable to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Stone Free Rates Measured using Chi-Square analysis.3 months.Rate of clearance of kidney stones following the procedure.
Number of Participants with Repeat procedures3 months.Number of Participants requiring repeat surgical procedures for residual stones following initial treatment.

Secondary

MeasureTime frameDescription
Length of hospital stay3 months.Hospital stay for simultaneous bilateral versus staged PCNL.
Number of Participants with Complications3 months.Number of participants with perioperative complication and rates for each procedure.
Patient Quality of Life3 months.Quality of life assessment comparing the two different procedures will be conducted with the Wisconsin Stone Quality of Life questionnaire (WISQOL). WISQOL is a disease-specific, health-related quality of life measure designed for patients who form kidney stones. This questionnaire has 4 different domains: social-domain 1, emotional-domain 2, stone related-domain 3 and vitality-domain 4. In the questionnaire, patients are to answer between 1 (Very true) to 5 (Not true at all). 1 is the worst outcome, and 5 is the best outcome.

Countries

Canada

Contacts

Primary ContactVictor Wong
kfvwong@alumni.ubc.ca604-875-4111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026